BRTX - CIK 0001505497
The table below shows BioRestorative Therapies, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.79M | -$8.23M | -$6.43M | -$5.91M | -$3.33M | -$1.96M |
| Capital expenditure | $116.07K | $106.19K | $171.04K | $265.22K | $30.66K | - |
| Investing cash flow | $8.90M | $514.53K | $3.25M | -$13.40M | -$30.66K | - |
| Dividends paid | - | - | - | - | - |
BioRestorative Therapies, Inc. reported operating cash flow of -$10.79M for fiscal year 2025. That is down 31.1% from -$8.23M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.67M (FY 2013) to -$10.79M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $0.00 | - | - | - | - | - |
| Financing cash flow | $2.85M | $7.38M | $2.35M | - | $21.32M | $5.03M |